Detection of SARS-CoV-2 and other RNA Virus (Diagnostic)
In May 2022, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), MPP signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
Among these COVID-19 technologies for diagnostics:
Detection of SARS-CoV-2 and other RNA Virus Using a Novel Improved RT-qPCR Method that Increases Detection Sensitivity and Improves Safety:
NEI researchers discovered a technique for isolating SARS-CoV-2 from patient samples that increases yield and safety while reducing cost and prep time. Key to the method is a chelating agent called Chelex 100 resin made by the company Bio-Rad that preserves SARS-CoV-2 RNA in patient samples. The RNA prep method inactivates the virus, making positive samples safer for lab personnel to handle. Once extracted, the RNA is amplified to detectable levels using reverse transcription PCR (RT-qPCR), a widely used lab technique.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
|Aim of the licences||To facilitate the manufacture and commercialisation of Covid-19 related health products and vaccines around the world|
|Technology||One licence covers different patents and materials on technologies potentially relevant in the fight against COVID-19. The second licence specifically covers patents on the spike protein.|
|Products||Any product or vaccine that is covered by the Patents or Patent Applications or uses the Licensed Material.|
|Field of use||While one licence on the different technologies is granted for SARS-CoV-2 products for the WHO C-TAP program, the second licence, in relation to spike protein, refers to SARS-CoV-2 vaccines for the WHO C-TAP program.|
|Term||Continuing until the date the last Patent has lapsed, expired, or been invalidated|
|Scope of the grant||Non-exclusive right to grant royalty-bearing sublicences to develop the licensed patents/material into licensed products or vaccines, and to commercialise the licensed products or vaccines|
|Sublicence||MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence|